Payden & Rygel Gilead Sciences, Inc. Transaction History

Payden & Rygel

$1.24 Billion
Q2 2024

A detailed history of Payden & Rygel transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Payden & Rygel holds 180 shares of GILD stock, worth $15,854. This represents 0.0% of its overall portfolio holdings.

Number of Shares

180

Previous 2,680 93.28%

Holding current value

$15,854

Previous $201,000 94.03%

% of portfolio

0.0%

Previous 0.01%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 07, 2024	SELL	$63.15 - $72.88 $157,875 - $182,200	-2,500 Reduced 93.28%	180 $12,000
Q1 2024 Oct 08, 2024	BUY	$71.58 - $87.29 $178,950 - $218,225	2,500 Added 1388.89%	2,680 $196,000
Q2 2023 Aug 10, 2023	SELL	$76.01 - $86.7 $662,807 - $756,024	-8,720 Reduced 76.49%	2,680 $207,000
Q1 2022 Apr 13, 2022	SELL	$57.92 - $72.58 $16.8 Million - $21.1 Million	-290,300 Reduced 96.22%	11,400 $678,000
Q4 2021 Feb 11, 2022	BUY	$64.88 - $73.64 $19.6 Million - $22.2 Million	301,700 New	301,700 $21.9 Million
Q1 2021 May 13, 2021	SELL	$60.0 - $68.46 $84,000 - $95,843	-1,400 Closed	0 $0
Q3 2020 Nov 10, 2020	SELL	$62.1 - $78.08 $1.2 Million - $1.51 Million	-19,400 Reduced 93.27%	1,400 $88,000
Q1 2020 May 04, 2020	BUY	$62.63 - $80.22 $75,156 - $96,264	1,200 Added 6.12%	20,800 $1.56 Million
Q4 2019 Jan 31, 2020	SELL	$61.62 - $67.78 $197,184 - $216,896	-3,200 Reduced 14.04%	19,600 $1.27 Million
Q1 2019 May 08, 2019	SELL	$62.53 - $70.05 $15.6 Million - $17.5 Million	-250,200 Reduced 91.65%	22,800 $1.48 Million
Q4 2018 Jan 25, 2019	BUY	$60.54 - $79.0 $1.1 Million - $1.44 Million	18,200 Added 7.14%	273,000 $17.1 Million
Q3 2018 Nov 07, 2018	BUY	$71.28 - $78.92 $228,096 - $252,544	3,200 Added 1.27%	254,800 $19.7 Million
Q4 2017 Feb 06, 2018	BUY	$71.15 - $83.52 $35,575 - $41,760	500 Added 0.2%	251,600 $18 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $18.1 Million - $21.5 Million	251,100	251,100 $20.3 Million

Others Institutions Holding GILD

# of Institutions

1,893

Shares Held

1.02B

Call Options Held

12M

Put Options Held

9.04M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Payden & Rygel, based on Form 13F filings with the SEC.

News

Stay updated on Payden & Rygel with notifications on news.

Account